> Details

Gauthé, Mathieu; Sargos, Paul; Barret, Eric; Fromont-Hankard, Gaëlle; Beauval, Jean-Baptiste; Brureau, Laurent; Créhange, Gilles; Renard-Penna, Raphaële; Dariane, Charles; Fiard, Gaëlle; Mathieu, Romain; Roubaud, Guilhem; Ruffion, Alain; Rouprêt, Morgan; Ploussard, Guillaume

Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review
  • Contributor: Gauthé, Mathieu; Sargos, Paul; Barret, Eric; Fromont-Hankard, Gaëlle; Beauval, Jean-Baptiste; Brureau, Laurent; Créhange, Gilles; Renard-Penna, Raphaële; Dariane, Charles; Fiard, Gaëlle; Mathieu, Romain; Roubaud, Guilhem; Ruffion, Alain; Rouprêt, Morgan; Ploussard, Guillaume
  • imprint: MDPI AG, 2021
  • Published in: Journal of Clinical Medicine
  • Language: English
  • DOI: 10.3390/jcm10214909
  • ISSN: 2077-0383
  • Keywords: General Medicine
  • Origination:
  • Footnote:
  • Description: <jats:p>Background: Prostate-specific membrane antigen (PSMA) is not sufficiently overexpressed in a small proportion of prostate cancer (PCa) patients, who require other strategies for imaging and/or treatment. We reviewed potential targets other than PSMA for PCa theranostics in nuclear medicine that have already been tested in humans. Methods: We performed a systematic web search in the PubMed and Cochrane databases, with no time restrictions by pooling terms (“prostate cancer”, “prostatic neoplasms”) and (“radioligand”, “radiotracer”). Included articles were clinical studies. The results were synthetized by the target type. Results: We included 38 studies on six different targets: gastrin-releasing peptide receptors (GRPRs) (n = 23), androgen receptor (n = 11), somatostatin receptors (n = 6), urokinase plasminogen activator surface receptor (n = 4), fibroblast activation protein (n = 2 studies) and integrin receptors (n = 1). GRPRs, the most studied target, has a lower expression in high-grade PCa, CRPC and bone metastases. Its use might be of higher interest in treating earlier stages of PCa or low-grade PCa. Radiolabeled fibroblast activation protein inhibitors were the most recent and promising molecules, but specific studies reporting their interest in PCa are needed. Conclusion: Theranostics in nuclear medicine will continue to develop in the future, especially for PCa patients. Targets other than PSMA exist and deserve to be promoted.</jats:p>
  • Access State: Open Access